Loading stock data…
VIR
$9.26-0.14 (-1.49%)
Market OpenUpdated 12:37 PM EDT
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vir Biotechnology, Inc. in the Healthcare sector is trading at $9.26. Wall Street consensus targets $20.56 (9 analysts), implying a +122.0% move over the next 12 months. The stock is currently 21% below its 52-week high of $11.66, remaining 33.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +122.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$9.26
Potential Downside
0%
Whystock Fair Value$9.26
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$20.56+122.0%
Range$16.00 – $30.00
Fundamentals
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.67B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.66
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-71.90%
Volume
Today's trading volume
337,841
Recent News
Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
It's been a mediocre week for Vir Biotechnology, Inc. ( NASDAQ:VIR ) shareholders, with the stock dropping 10% to...
A Look At Vir Biotechnology (VIR) Valuation After The Astellas Partnership And Pipeline Progress
Vir Biotechnology (VIR) stock is back in focus after the company reported a first quarter 2026 net loss, alongside a multibillion-dollar collaboration with Astellas around prostate cancer candidate VIR-5500. See our latest analysis for Vir Biotechnology. The share price reaction has been volatile, with a 9.9% one day decline and 9.3% 7 day share price pullback following the earnings loss and Astellas deal. However, the 90 day share price return of 28.9% and 1 year total shareholder return of...
Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors.
Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent filings.
Vir Biotechnology Q1 Earnings Call Highlights
Vir Biotechnology (NASDAQ:VIR) reported first-quarter 2026 financial results and provided pipeline updates, highlighting progress across its oncology programs and its registrational hepatitis delta virus (HDV) effort. Management also discussed the closing of a global collaboration with Astellas focu
Vir Biotechnology, Inc. Q1 2026 Earnings Call Summary
Moby summary of Vir Biotechnology, Inc.'s Q1 2026 earnings call